0001209191-23-024879.txt : 20230419
0001209191-23-024879.hdr.sgml : 20230419
20230419174003
ACCESSION NUMBER: 0001209191-23-024879
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230417
FILED AS OF DATE: 20230419
DATE AS OF CHANGE: 20230419
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: TRENARY C RUSSELL III
CENTRAL INDEX KEY: 0001227307
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37759
FILM NUMBER: 23830896
MAIL ADDRESS:
STREET 1: 1700 E ST ANDREW PLACE
CITY: SANTA ANA
STATE: CA
ZIP: 92705
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Outlook Therapeutics, Inc.
CENTRAL INDEX KEY: 0001649989
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 383982704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 485 ROUTE 1 SOUTH
STREET 2: BUILDING F, SUITE 320
CITY: ISELIN
STATE: NJ
ZIP: 08830
BUSINESS PHONE: 6096193990
MAIL ADDRESS:
STREET 1: 485 ROUTE 1 SOUTH
STREET 2: BUILDING F, SUITE 320
CITY: ISELIN
STATE: NJ
ZIP: 08830
FORMER COMPANY:
FORMER CONFORMED NAME: Oncobiologics, Inc.
DATE OF NAME CHANGE: 20150804
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-04-17
0
0001649989
Outlook Therapeutics, Inc.
OTLK
0001227307
TRENARY C RUSSELL III
485 ROUTE 1 SOUTH, BUILDING F
SUITE 320
ISELIN
NJ
08830
1
1
0
0
CEO and President
0
Stock Option (Right to Buy)
1.08
2023-04-17
4
A
0
257143
0.00
A
2033-04-17
Common Stock
257143
257143
D
25% of the shares subject to the option shall vest on April 17, 2024, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances.
/s/ Lawrence Kenyon, Attorney-in-Fact
2023-04-19